HRP20240211T1 - Novi kristalni oblici tienopirimidina kao mcl-1 inhibitora - Google Patents
Novi kristalni oblici tienopirimidina kao mcl-1 inhibitora Download PDFInfo
- Publication number
- HRP20240211T1 HRP20240211T1 HRP20240211TT HRP20240211T HRP20240211T1 HR P20240211 T1 HRP20240211 T1 HR P20240211T1 HR P20240211T T HRP20240211T T HR P20240211TT HR P20240211 T HRP20240211 T HR P20240211T HR P20240211 T1 HRP20240211 T1 HR P20240211T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- cancer
- crystalline form
- expressed
- theta
- Prior art date
Links
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 title 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- RBNBDIMXFJYDLQ-UHFFFAOYSA-N thieno[3,2-d]pyrimidine Chemical compound C1=NC=C2SC=CC2=N1 RBNBDIMXFJYDLQ-UHFFFAOYSA-N 0.000 title 1
- 229940126062 Compound A Drugs 0.000 claims 32
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 32
- 238000000634 powder X-ray diffraction Methods 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 201000004101 esophageal cancer Diseases 0.000 claims 3
- 210000000987 immune system Anatomy 0.000 claims 3
- 201000007270 liver cancer Diseases 0.000 claims 3
- 208000014018 liver neoplasm Diseases 0.000 claims 3
- 208000003747 lymphoid leukemia Diseases 0.000 claims 3
- 230000003211 malignant effect Effects 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 3
- 239000002904 solvent Substances 0.000 claims 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims 3
- 206010046766 uterine cancer Diseases 0.000 claims 3
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 230000005540 biological transmission Effects 0.000 claims 2
- 238000001875 carbon-13 cross-polarisation magic angle spinning nuclear magnetic resonance spectrum Methods 0.000 claims 2
- 238000002425 crystallisation Methods 0.000 claims 2
- 230000008025 crystallization Effects 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- -1 glidants Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 239000003381 stabilizer Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- PKYIMGFMRFVOMB-UHFFFAOYSA-N 2-[5-[3-chloro-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid Chemical compound ClC=1C(=C(C=CC=1OCCN1CCN(CC1)C)C1=C(SC=2N=CN=C(C=21)OC(C(=O)O)CC1=C(C=CC=C1)OCC1=NC(=NC=C1)C1=C(C=CC=C1)OC)C1=CC=C(C=C1)F)C PKYIMGFMRFVOMB-UHFFFAOYSA-N 0.000 claims 1
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 claims 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (30)
1. Kristalni oblik 2-{[5-{3-Kloro-2-metil-4-[2-(4-metilpiperazin-1-il)etoksi]fenil}-6-(4-fluorofenil)tieno[2,3-d]pirimidin-4-il]oksi}-3-(2-{[2-(2-metoksifenil)pirimidin-4-il]metoksi}fenil)propanske kiseline (Spoj A).
2. Kristalni oblik Spoja A prema patentnom zahtjevu 1, imajući čistoću veću od 90 % masenog udjela.
3. Kristalni oblik Spoja A prema patentnom zahtjevu 1 ili patentnom zahtjevu 2, naznačen time što ima dijagram rendgenske difrakcije praha koji pokazuje barem sljedeće difrakcijske linije (Braggov kut 2 theta, izražen u stupnjevima ± 0,2°): 8,94 i 18,24.
4. Kristalni oblik Spoja A prema patentnom zahtjevu 1 ili patentnom zahtjevu 2, naznačen time što ima dijagram rendgenske difrakcije praha koji prikazuje barem 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 ili sve sljedeće difrakcijske linije (Braggov kut 2 theta, izražen u stupnjevima ± 0,2°): 6,27; 8,94; 9.09; 12,16; 13,67; 14,75; 15,06; 16,97; 17.22; 17,44; 18,24; 19,16; 19,93; 20,91; 25,88.
5. Kristalni oblik Spoja A prema patentnom zahtjevu 4, naznačen time što ima dijagram rendgenske difrakcije praha koji ima sljedeće difrakcijske linije (Braggov kut 2 theta, izražen u stupnjevima ± 0,2°): 8,94; 13.67; 14.75; 17.22; 18.24.
6. Kristalni oblik Spoja A prema patentnom zahtjevu 4, naznačen time što ima dijagram rendgenske difrakcije praha koji ima sljedeće difrakcijske linije (Braggov kut 2 theta, izražen u stupnjevima ± 0,2°): 6,27; 8,94; 9,09; 12,16; 13,67; 14,75; 15,06; 16,97; 17,22; 17,44; 18,24; 19,16; 19,93; 20,91; 25,88.
7. Kristalni oblik Spoja A prema patentnom zahtjevom 6, naznačen time što ima sljedeći dijagram rendgenske difrakcije praha, izmjeren u „spinner“ načinu prijenosa pomoću PANalytical Empyrean difraktometra s PIXcell 1D detektorom i izražen u smislu položaja linije (Braggova kut 2 theta, izražen u stupnjevima ± 0,2°) i međuplanarne udaljenosti d (izražene u Å):
[image]
8. Kristalni oblik Spoja A prema bilo kojem od patentnih zahtjeva 1 do 7, naznačen time što ima 13C CP/MAS NMR spektar čvrstog stanja koji ima sljedeće maksimume (izražene u ppm ± 0,2 ppm): 175,1, 153,7, 134,8, 108,9, 71,4 i 35,1.
9. Kristalni oblik Spoja A prema bilo kojem od patentnih zahtjeva 1 do 7, naznačen time što ima 13C CP/MAS NMR spektar čvrstog stanja koji ima sljedeće maksimume (izražene u ppm ± 0,2 ppm): 175,1, 168,5, 167,4, 164,6, 162,6, 157,5, 156,3, 153,7, 135,5, 134,8, 130,4, 129,9, 128,4, 126,8, 120,9, 119,9, 118,5, 116,9, 112,5, 111,1, 108, 9, 78,7, 71,4, 54,9, 42,1, 35,1 i 18,2.
10. Farmaceutski sastav koji kao aktivni sastojak sadrži kristalni oblik Spoja A, prema bilo kojem od patentnih zahtjeva 1 do 9 u vezi s jednim ili više farmaceutski prihvatljivih nosača, sredstava za klizanje, razrjeđivača, pomoćnih tvari ili stabilizatora.
11. Farmaceutski sastav prema patentnom zahtjevu 10, za upotrebu u liječenju raka, autoimunih bolesti i bolesti imunološkog sustava.
12. Farmaceutski sastav za upotrebu prema patentnom zahtjevu 11, pri čemu je rak odabran između raka mokraćnog mjehura, raka mozga, raka dojke, raka maternice, kroničnih limfoidnih leukemija, kolorektalnog raka, raka jednjaka, raka jetre, limfoblastičnih leukemija, akutne mijeloične leukemije, limfoma, melanoma, malignih hemopatija, mijeloma, raka jajnika, raka pluća nemalih stanica, raka prostate i raka pluća malih stanica.
13. Kristalni oblik Spoja A prema bilo kojem od patentnih zahtjeva 1 do 9, za upotrebu kao lijek.
14. Kristalni oblik Spoja A prema bilo kojem od patentnih zahtjeva 1 do 9, za upotrebu u liječenju raka, autoimunih bolesti i bolesti imunološkog sustava.
15. Kristalni oblik Spoja A za upotrebu prema patentnom zahtjevu 14, pri čemu je rak odabran između raka mokraćnog mjehura, raka mozga, raka dojke, raka maternice, kroničnih limfoidnih leukemija, kolorektalnog raka, raka jednjaka, raka jetre, limfoblastičnih leukemija, akutne mijeloične leukemije, limfome, melanome, malignih hemopatija, mijeloma, raka jajnika, raka pluća nemalih stanica, raka prostate i raka pluća malih stanica.
16. Postupak za pripremu kristalnog oblika Spoja A prema bilo kojem od patentnih zahtjeva 1 do 9, pri čemu je Spoj A kristaliziran u otapalu odabranom između toluena, 2-metiltetrahidrofurana ili mješavine toluena i metil tert-butil etera.
17. Postupak za pripremu kristalnog oblika Spoja A prema patentnom zahtjevu 16, pri čemu je Spoj A kristalni oblik Spoja A prema bilo kojem od patentnih zahtjeva 22 do 27.
18. Postupak za pripremu kristalnog oblika Spoja A prema patentnom zahtjev 16 ili patentnom zahtjev 17, pri čemu je koncentracija Spoja A u otapalu između 5 do 15 % m/m.
19. Postupak za pripremu kristalnog oblika Spoja A prema bilo kojem od patentnih zahtjeva 16 do 18, pri čemu se suspenzija dobivena tijekom procesa suši između 20 °C i 80 °C.
20. Postupak za pripremu kristalnog oblika Spoja A prema bilo kojem od patentnih zahtjeva 16 do 18, u kojem je kristalizacija zasijana upotrebom vrlo male količine kristalnog oblika Spoja A prema bilo kojem od patentnih zahtjeva 1 do 9.
21. Postupak za pripremu kristalnog oblika Spoja A prema patentnom zahtjevu 20, pri čemu je kristalizacija zasijana na temperaturi koja se nalazi između 20 °C i 60 °C.
22. Kristalni oblik Spoja A prema patentnom zahtjevu 1, naznačen time što ima dijagram rendgenske difrakcije praha koji pokazuje barem sljedeće difrakcijske linije (Braggov kut 2 theta, izražen u stupnjevima ± 0,2°): 7,52 i 16,61.
23. Kristalni oblik Spoja A prema patentnom zahtjevu 1, naznačen time što ima dijagram rendgenske difrakcije praha koji prikazuje barem 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 ili sve sljedeće difrakcijske linije (Braggov kut 2 theta, izražen u stupnjevima ± 0,2°): 7,52; 8,89; 9,58; 10,35; 11,25; 13,08; 14,44; 16,61; 17,07; 17,71; 19,10; 20,60; 20,80; 21,69; 22,14; 23,63; 27,36.
24. Kristalni oblik Spoja A prema patentnom zahtjevu 23, naznačen time što ima dijagram rendgenske difrakcije praha koji ima sljedeće difrakcijske linije (Braggov kut 2 theta, izražen u stupnjevima ± 0,2°): 7,52; 8,89; 10,35; 16,61; 19,10.
25. Kristalni oblik Spoja A prema patentnom zahtjevu 23, naznačen time što ima dijagram rendgenske difrakcije praha koji ima sljedeće difrakcijske linije (Braggov kut 2 theta, izražen u stupnjevima ± 0,2°): 7,52; 8,89; 9,58; 10,35; 11,25; 13,08; 14,44; 16,61; 17,07; 17,71; 19,10; 20,60; 20,80; 21,69; 22,14; 23.63; 27.36.
26. Kristalni oblik spoja A prema patentnom zahtjevu 25, naznačen time što ima sljedeći dijagram rendgenske difrakcije praha, izmjeren u „spinner“ načinu prijenosa pomoću PANalytical Empyrean difraktometra s PIXcell 1D detektorom i izražen u smislu položaja linije (Braggov kut 2 theta, izražen u stupnjevima ± 0,2°) i međuplanarne udaljenosti d (izražena u Å):
[image]
27. Farmaceutski sastav koji kao aktivni sastojak sadrži kristalni oblik Spoja A, prema bilo kojem od patentnih zahtjeva 22 do 26 u kombinaciji s jednim ili više farmaceutski prihvatljivih nosača, sredstava za klizanje, razrjeđivača, pomoćnih tvari ili stabilizatora.
28. Farmaceutski sastav prema patentnom zahtjevu 27 za upotrebu u liječenju raka, autoimunih bolesti i bolesti imunološkog sustava.
29. Farmaceutski sastav za upotrebu prema patentnom zahtjevu 28, pri čemu je rak odabran između raka mokraćnog mjehura, raka mozga, raka dojke, raka maternice, kroničnih limfoidnih leukemija, kolorektalnog raka, raka jednjaka, raka jetre, limfoblastičnih leukemija, akutne mijeloične leukemije, limfoma, melanoma, maligne hemopatije, mijeloma, raka jajnika, raka pluća nemalih stanica, raka prostate, raka gušterače i raka pluća malih stanica.
30. Postupak za pripremu kristalnog oblika Spoja A prema bilo kojem od patentnih zahtjeva 22 do 26, pri čemu je Spoj A kristaliziran u otapalu odabranom između dimetoksi-1,2-etana ili mješavine dimetoksi-1,2-etana i di-izopropiletera.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18306634 | 2018-12-06 | ||
| EP19817229.8A EP3891156B1 (en) | 2018-12-06 | 2019-12-05 | New crystalline forms of a thienopyrimidine as mcl-1 inhibitor |
| PCT/EP2019/083773 WO2020115183A1 (en) | 2018-12-06 | 2019-12-05 | New crystalline forms of a mcl-1 inhibitor, a process for their preparation and pharmaceutical compositions containing them. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240211T1 true HRP20240211T1 (hr) | 2024-04-26 |
Family
ID=64665802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240211TT HRP20240211T1 (hr) | 2018-12-06 | 2019-12-05 | Novi kristalni oblici tienopirimidina kao mcl-1 inhibitora |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20220017533A1 (hr) |
| EP (1) | EP3891156B1 (hr) |
| JP (1) | JP2022511495A (hr) |
| KR (1) | KR20210100148A (hr) |
| CN (1) | CN113166169A (hr) |
| AR (1) | AR117255A1 (hr) |
| AU (1) | AU2019391329A1 (hr) |
| BR (1) | BR112021010072A2 (hr) |
| CA (1) | CA3121363A1 (hr) |
| DK (1) | DK3891156T3 (hr) |
| EA (1) | EA202191534A1 (hr) |
| ES (1) | ES2971258T3 (hr) |
| FI (1) | FI3891156T3 (hr) |
| HR (1) | HRP20240211T1 (hr) |
| HU (1) | HUE065266T2 (hr) |
| IL (1) | IL283656A (hr) |
| LT (1) | LT3891156T (hr) |
| MA (1) | MA54379B1 (hr) |
| MX (1) | MX2021006702A (hr) |
| PL (1) | PL3891156T3 (hr) |
| PT (1) | PT3891156T (hr) |
| RS (1) | RS65047B1 (hr) |
| SI (1) | SI3891156T1 (hr) |
| TW (1) | TW202039511A (hr) |
| WO (1) | WO2020115183A1 (hr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240019283A (ko) | 2021-06-11 | 2024-02-14 | 길리애드 사이언시즈, 인코포레이티드 | Mcl-1 저해제와 항암제의 병용 |
| US11931424B2 (en) | 2021-06-11 | 2024-03-19 | Gilead Sciences, Inc. | Combination MCL-1 inhibitors with anti-body drug conjugates |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3015483B1 (fr) * | 2013-12-23 | 2016-01-01 | Servier Lab | Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3037957B1 (fr) * | 2015-06-23 | 2019-01-25 | Les Laboratoires Servier | Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3046792B1 (fr) * | 2016-01-19 | 2018-02-02 | Les Laboratoires Servier | Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
2019
- 2019-12-05 US US17/295,521 patent/US20220017533A1/en active Pending
- 2019-12-05 EP EP19817229.8A patent/EP3891156B1/en active Active
- 2019-12-05 BR BR112021010072-5A patent/BR112021010072A2/pt unknown
- 2019-12-05 RS RS20240001A patent/RS65047B1/sr unknown
- 2019-12-05 JP JP2021531796A patent/JP2022511495A/ja active Pending
- 2019-12-05 CN CN201980080579.8A patent/CN113166169A/zh active Pending
- 2019-12-05 WO PCT/EP2019/083773 patent/WO2020115183A1/en active Application Filing
- 2019-12-05 HR HRP20240211TT patent/HRP20240211T1/hr unknown
- 2019-12-05 FI FIEP19817229.8T patent/FI3891156T3/fi active
- 2019-12-05 PL PL19817229.8T patent/PL3891156T3/pl unknown
- 2019-12-05 TW TW108144437A patent/TW202039511A/zh unknown
- 2019-12-05 DK DK19817229.8T patent/DK3891156T3/da active
- 2019-12-05 PT PT198172298T patent/PT3891156T/pt unknown
- 2019-12-05 KR KR1020217020808A patent/KR20210100148A/ko unknown
- 2019-12-05 HU HUE19817229A patent/HUE065266T2/hu unknown
- 2019-12-05 SI SI201930704T patent/SI3891156T1/sl unknown
- 2019-12-05 EA EA202191534A patent/EA202191534A1/ru unknown
- 2019-12-05 ES ES19817229T patent/ES2971258T3/es active Active
- 2019-12-05 CA CA3121363A patent/CA3121363A1/en active Pending
- 2019-12-05 LT LTEPPCT/EP2019/083773T patent/LT3891156T/lt unknown
- 2019-12-05 AU AU2019391329A patent/AU2019391329A1/en active Pending
- 2019-12-05 MA MA54379A patent/MA54379B1/fr unknown
- 2019-12-05 MX MX2021006702A patent/MX2021006702A/es unknown
- 2019-12-05 AR ARP190103554A patent/AR117255A1/es unknown
-
2021
- 2021-06-02 IL IL283656A patent/IL283656A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT3891156T (pt) | 2024-01-16 |
| DK3891156T3 (da) | 2024-02-19 |
| CA3121363A1 (en) | 2020-06-11 |
| CN113166169A (zh) | 2021-07-23 |
| AR117255A1 (es) | 2021-07-21 |
| EP3891156A1 (en) | 2021-10-13 |
| SI3891156T1 (sl) | 2024-03-29 |
| TW202039511A (zh) | 2020-11-01 |
| IL283656A (en) | 2021-07-29 |
| WO2020115183A1 (en) | 2020-06-11 |
| AU2019391329A1 (en) | 2021-07-01 |
| MA54379A (fr) | 2021-10-13 |
| RS65047B1 (sr) | 2024-02-29 |
| BR112021010072A2 (pt) | 2021-08-24 |
| FI3891156T3 (fi) | 2024-02-07 |
| EA202191534A1 (ru) | 2021-10-27 |
| MA54379B1 (fr) | 2023-12-29 |
| PL3891156T3 (pl) | 2024-05-13 |
| KR20210100148A (ko) | 2021-08-13 |
| ES2971258T3 (es) | 2024-06-04 |
| HUE065266T2 (hu) | 2024-05-28 |
| LT3891156T (lt) | 2023-12-27 |
| JP2022511495A (ja) | 2022-01-31 |
| EP3891156B1 (en) | 2023-11-15 |
| US20220017533A1 (en) | 2022-01-20 |
| MX2021006702A (es) | 2021-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102061917B1 (ko) | 선택적인 herb2 저해제인 arry-380의 다형체 및 이를 함유하는 약제학적 조성물 | |
| HRP20192073T1 (hr) | Novi derivati amonija, postupak za njihovu pripravu te farmaceutski pripravci koji ih sadrže | |
| JP6322770B2 (ja) | Ｅｒｋ阻害剤 | |
| RU2014151850A (ru) | Новые тиенопиримидиновые производные, способ их получения и фармацевтические композиции, содержащие их | |
| ES2875360T3 (es) | Derivado de piridona que tiene un grupo tetrahidropiranil metilo | |
| RU2018102365A (ru) | Новые гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их | |
| HRP20240211T1 (hr) | Novi kristalni oblici tienopirimidina kao mcl-1 inhibitora | |
| EP2986300A2 (en) | 3,5-(un)substituted-1h-pyrrolo[2,3-b]pyridine, 1h-pyrazolo[3,4-b]pyridine and 5h-pyrrolo [2-,3-b]pyrazine dual itk and jak3 kinase inhibitors | |
| CN112851663B (zh) | 一种并杂环化合物及其用途 | |
| WO2022028598A1 (en) | Atr inhibitors and uses thereof | |
| RU2021132394A (ru) | Кристаллическая фумаратная соль (s)-[3,4-дифтор-2-(2-фтор-4-йодфениламино)фенил][3-гидрокси-3-(пиперидин-2-ил)азетидин-1-ил]метанона | |
| KR101129088B1 (ko) | Ｎ-［6-(시스-2,6-디메틸모르폴린-4-일)피리딘-3-일］-2-메틸-4'-(트리플루오로메톡시)［1,1'-비페닐］-3-카르복스아미드의 염 | |
| CA2997531A1 (en) | Tricyclic fused pyridin-2-one derivatives and their use as brd4 inhibitors | |
| WO2023284537A1 (en) | Kras g12d inhibitors and uses thereof | |
| HRP20230563T1 (hr) | Nova sol bcl-2 inhibitora, srodni kristalni oblik, postupak za pripravu istih i farmaceutski pripravci koji ih sadrže | |
| ES2553248T3 (es) | Lactonas tricíclicas para el tratamiento del cáncer | |
| SG172181A1 (en) | Derivatives of 6-cycloamino-2,3-di-pyridinyl-imidazo[1,2-b]-pyridazine, preparation and therapeutic application thereof | |
| AU2016242473A1 (en) | Tricyclic fused derivatives of 1-(cyclo)alkyl pyridin-2-one useful for the treatment of cancer | |
| AU2019344398B2 (en) | Cyclic dinucleotide analogue, pharmaceutical composition thereof, and application | |
| US20210198261A1 (en) | Aurora kinase inhibitors and uses thereof | |
| JP2010111702A (ja) | 複素環化合物、その製造法および用途 | |
| CA3093323A1 (en) | Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof | |
| WO2023030517A1 (en) | Kras g12c inhibitors and uses thereof | |
| CN116134022A (zh) | Atr抑制剂和其用途 | |
| RU2021119029A (ru) | Новые кристаллические формы mcl-1 ингибитора, способ их получения и содержащие их фармацевтические композиции |